Reforming 340B to Serve the Interests of Patients, Not Institutions

This Viewpoint discusses reforms to the 340B Drug Pricing Program to focus revenues from the program on lower-income and uninsured patients.

from JAMA Health Forum New Online https://ift.tt/chDEJ5S